Loading stock data…
ENDRA Life Sciences Inc. (NDRA)
$5.91-0.14 (-2.40%)
Market ClosedLast close Sep 8
ENDRA Life Sciences Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ENDRA Life Sciences Inc. in the Healthcare sector is trading at $5.91 with a market capitalization of $9M. Wall Street consensus targets $25.00 (1 analysts), implying a +323.4% move over the next 12 months. The stock is currently 40% below its 52-week high of $9.85, remaining 24.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +323.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.48M↑ | -$2.17M↓ | -$1.62M↓ | -$1.37M↓ | -$1.30M |
| Net Income | $159,944↑ | -$1.31M↑ | -$3.17M↓ | -$1.60M↓ | -$1.23M |
Peer Comparison
JNJUNHPFE
Fundamentals
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio fr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-93.77%
Volume
Today's trading volume
2,697
Recent News
ASP Isotopes Maps Noble Africa Listing as Helium Project Nears Production
ASP Isotopes (NASDAQ:ASPI) executives outlined plans to create a publicly listed helium and liquefied natural gas platform through Noble Africa, emphasizing Renergen’s South African helium resource, expected near-term production milestones and the proposed merger with ENDRA Life Sciences. Paul Mann
Top Midday Decliners
ASP Isotopes (ASPI) said Thursday its Noble Africa unit will merge with a subsidiary of Endra Life S
ASP Isotopes To Merge Noble Africa With A Unit Of ENDRA – A Look At The Key Contours Of The Deal
ASP Isotopes is expected to own approximately 89% of the combined company, with ENDRA shareholders owning 3%.
NDRA's TAEUS Device Achieves MRI-Level Liver Imaging Precision
ENDRA posts strong TAEUS Liver study data, showing high measurement reliability for MASLD monitoring and boosting its regulatory and commercial outlook.
Endra Life Sciences commences staking of HYPE digital asset holdings
ENDRA Life Sciences (NDRA) announced it has commenced staking its holdings of HYPE (HYPE-USD), the native token of the Hyperliquid ecosystem. The company said the move is designed to maximize the utility and return of its HYPE treasury. The initiative is guided by ARCA Investment Management and secured by Anchorage Digital. “Commencing our HYPE staking program is an essential evolution of our digital asset strategy,” said Alexander Tokman, CEO of ENDRA. “By partnering with industry leaders ARCA